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are significantly correlated to the underactive detrusor in EDS patients with or
without OT.
Can we explain this by the conjunctive tissue modification due to EDS? There is
a strong correlation between underactive detrusor, respectively PVR and OT. So
we can’t conclude to any LUTS specific to EDS.
Conclusion.– Dysuria and PVR are frequent in EDS but strongly correlated with
the OT.
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Objective.– To determine in daily practice, the failure rate of treatment with
Botox1 300UI of NDO and analyze the causes of failure and their
predictors.
Method.– Retrospective (2002–2011) monocentric study of patients with
overactive bladder, treated with 300 IU Botox1 and self-catheterized. The
evaluation criteria were clinical, urodynamic and ultrasound.
The time to occurrence of failures was estimated by the Kaplan Meir. Groups
were compared by the log rank test and Cox model.
Results.– One hundred and eighty-three patients were included (165 SCI, 18
multiple sclerosis (MS)). At 3 years, 152 patients continued injections of
intravesical botulinum toxin (83%) and 138 patients after 5 years (75.4%).
We differentiated the true failures (32 patients), from discontinuation of
treatment for side effects, poor tolerance of injections or neurological
outcome.
In the group of MS, there was only one true failure, other patients discontinued
treatment for other reasons, including the worsening of the disease.
In the group of patients who failed treatment, we find significantly in univariate
analysis:
–leakages after first injection, at 3 years (p<0.0001) and at 5 years (p<0.0001);
–presence of febrile urinary tract infection after 1st injection, at 3 years
(p = 0.01);
–existence of detrusor overactivity after first injection, at 3 years (p = 0.05);
–poor compliance before first injection, at 5 years (p = 0.04);
–maximum detrusor pressure after first injection, at 3 years (p = 0.005) and at 5
years (p = 0.0004).
In multivariate analysis, the following were significantly predictive of failure:
leakages after 1st injection a t 3 years (p = 0.01) and at 5 years (p = 0.0004), sex
of patients at 5 years (p = 0,01).
The rate of symptomatic urinary tract infections was significantly reduced after
toxin injection (p < 0.0001).
Conclusion.– This study, which is representative of daily practice in a neuro-
urology center, confirmed the effectiveness and safety of injections of 300 IU of
Botox1. Some factors seem predictive of failure of intra-detrusor botulinum
toxin (i.e. leakage after first injection).
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Introduction.– The aim was to evaluate neurologic patients with stable and
capacitive bladder under injections of intravesical botulinum toxin who are
unable to perform self-intermittent catheterization through the native urethra
who need continent vesicostomy, without augmentation enterocystoplasty.
Patients.– We identified all patients with stable neurogenic bladder under
injection of botulinum toxin realizing self-catheterization or by a helper but
unable to achieve them through unrethra, that underwent a continent
vesicostomy between 2008 and 2012. Indication, surgical technique,
complications, voiding method and quality of life were analysed.
Results.– We considered four women suffering from spinal cord injury (one) or
multiple sclerosis (three), unable to achieve self-catheterization through urethra
because of functionnal loss of upper limbs or adductors spasticity or increase of
weight. The surgical technique was vesicostomy using the Mitrofanoff
principle, without enterocystoplasty, because of bladder stability under médical
treatment and comorbidities; the native bladder was fixed to the inner face of the
abdominal wall. The mean operation time was 188 min. Minor complications
(stoma stenosis and wound dehiscence) and quality of life were not different
from patients who underwent enterocystoplasty. One patient had a Bricker three
years after first surgery.
Conclusion.– Injection of botulinum toxine for overactive bladder seems to be
an alternative to enterocystoplasty when realizing continent cystostomy in
neurologic patients with comorbidities like multiple sclerosis. However,
evolutivity of the pathology may lead to a second surgery due to inability to
achieve catheterization through urethra or loss of efficiency of botulinum toxin.
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Objectives.– Augmentation enterocystoplasty (AE) is a third-line treatment for
neurogenic detrusor overactivity (NDO). When the outcome of an AE is
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incomplete or comes to the end, botulinum toxin type A (BTX-A) injections in
the augmented bladder have been proposed. To date, this practice has not been
evaluated in the literature. The aim of our study was to describe the practice and
evaluate the results of detrusor injections of BTX-A in addition to an AE in
patients with refractory NDO.
Methods.– A retrospective multicenter study was conducted by members of the
‘‘Groupe de Neuro-Urologie de Langue Française’’ (GENULF), within nine
academic centers. All patients (n = 27) who benefited from an AE and a
supplementary detrusor injection of BTX-A for a NDO were included.
Clinical (epidemiological, surgical, functional) and uro-dynamic data (max-
imum cystometric capacity, detrusor pressure at first reflex detrusor contraction
and at maximum cystometric capacity, reflex detrusor volume, bladder
compliance) were collected from the medical files in a standardized
questionnaire.
Results.– Twenty-seven patients with various neurological disorders were
included: 12 congenital disorders (spina bifida, sacral agenesis), 10 spinal cord
injuries, two multiple sclerosis, and three neurogenic bladders of unknown
aetiology. AE was performed with ileum in 16 cases and côlon in eight cases.
Supratrigonal cystectomy was associated in 15 cases. Primary failure of AE
occured in 11 cases and delayed failure in 14 cases. In case of delayed failure,
the average duration between AE and failure was 10.4 years (1-26 years). BTX-
A injections improved the symptoms, completely or partly, in 15 of 27 cases
(55.5%). The clinical succes was associated with a request for reinjection in 14
patients (51,9%).
Conclusions.– In our study, BTX-A injections provided a clinically significant
benefit to 55.5% of patients. BTX-A injections are a treatment to consider in
case of refractory NDO as a last resort in a patient who previously had an AE.
http://dx.doi.org/10.1016/j.rehab.2013.07.598
CO41-006-e
Bacterial ecology and antibiotic resistance in
patients with neurogenic overactive bladder treated
by botulinum toxin injections
J. Levy *, F. le Breton, M. Jousse, R. Haddad, D. Verollet,
A. Guinet-Lacoste, G. Amarenco
Hôpital Tenon, AP–HP, 4, rue de la Chine, 75020 Paris, France
*Corresponding author.
E-mail address: levyjonathan2@gmail.com
Keywords: Botulinum toxin A; Neurogenic overactive bladder; Multiple
sclerosis; Spinal cord injury; Bacterial ecology; Antibiotic resistance
Botulinum toxin A is the gold standard fort the treatment of neurogenic
overactive bladder. These patients mostly use clean intermittent self
catheterization. Colonisations are frequent and detrusor injections are at risk
for infections.
Objective.– To study the prevalence of different bacterias and their resistance to
antibiotics in a population with neurogenic overactiv bladder treated with
botulinum toxin injections.
Material and methods.– This prospective study took place from september to
october 2012 in a neuro-urology unit in a universitary hospital. Eighty-one
patients had a uroculture before the injection. They all had on overactive bladder
confirmed by urodynamic study. We determined the prevalences of different
bacterias and their resistance rate for each antibiotic class.
Results.– Forty-six bacterias were identified on 45 urocultures. An Escherichia
coli was identified in 43.21%, 7.41% Klebsiella pneumoniae, 2.47%
Citrobacter freundii and enterococcus, 1.23% Staphylococcus aureus.
Penicillin resistance was found in 52.17%, to third generation cephalosporins
in 10.87%, to fluoroquinolon in 28.26% and to sulfamid in 26.09%. There was
no resistance for fosfomycin.
Discussion.– We found less colonisation rates than what’s described in the
litterature for patients using clean intermittent self catheterization (52% versus
60 to 70%). [1] There was no resistance to fosfomycin; however the benefit for
systematic prophylaxis in case of sterile uroculture had never been proven
(despite the recommendations for the French authorization of drug use in this
indication.) [2]
Conclusion.– We found high frequency of E. coli in patients using clean
intermittent catheterization. All bacteria were sensible to fosfomycin, which
suggest its preferential use for probabilistic prophylaxis before botulinum
injections for the treatment of neurogenic overactive bladder.
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